Publications

1. Biswas J, Tsuchiyia H , Roy PK, Tsuchida B. Spontaneous remission of cancer: evidence of thermal remission of tumours. Proc 5th conference of International Society of Radiation Physics.

2. Biswas J, PK Roy, D Dutta Majumder et al (1996) Biological parallelism in spontaneous regression of tumor and of neurogranuloma, Tumor Biology

3. Biswas J, Tsuchida B, Mori Y, Roy PK (1997) The Paradox of Sponteneous Cancer Regression: Implications for Stochastic Radiotherapy. Proc. of Satellite Conference of Radiation Physics.

4. Biswas J, Fenwick P, Roy PK (1997) A new approach to the unexplained phenomenon of Spontaneous Cancer Regression: non-linear dynamics & therapeutic implications. “Non-linear dynamics & biology”.

5. Biswas J, Tomita, Roy PK (1997) Can toxic syndrome cause spontaneous cancer regression? the paradoxical phenomenon: case studies & implications for cancer therapy. Proc. European Conference on Toxic Shock Syndrome.

6. Biswas J, Basu S et al (1999) The role of neoadjuvant and adjuvant chemotherapy regimens consisting of different combinations of drugs in the treatment of advanced oral cancer. Medical Oncology, 16: 199-203.

7. Murmu N , Mitra S, Das M, Gomes , Vedasiromoni JR, Ghosh M ,
Bhattacharya M, Ghosh P , Biswas J, Bhattacharya S , Sur P, (2001) Boron compounds against human leukemic cells. J Exp Clin Cancer Res, 20: 511-515.

8. Mondal A, Kundu B , Gupta S , Biswas J(2002) . Secondary malignant giant cell tumor of bone--a study of five cases with short review of literature. Indian J Pathol Microbiol. 45 (3): 273-275.

9. Mondal A, Kundu B, Ray CK, Saha DK, Biswas J, Misra DK (2002). Utility of imaging modalities in diagnostic FNAC. J Cytol;19:123-38.

10. Sinha AK, Acharya K, Bhattacharya S, Chakraborty Patra S, Guha M, Ray U , Basu Ray S, Khan GA, Chakraborty K, Biswas J, Sahana Mazumdar S (2002). Neutralization by "antineoplastin" of insulin-activated nitric oxide synthase antibody and its effects in cancers. J Cancer Res Clin Oncol.128 (12):659-668.

11. Guha M, Biswas J, Tirkey J, Sinha AK (2002). Impairment of stimulation by estrogen of insulin-activated nitric oxide synthase in human breast cancer. Int J Cancer. 20;100 (3):261-265.

12. Basu P, Biswas J, Mondol R, Choudhuri P (2006), Is interferon-α and retinoic acid combination along with radiation superior to chemo-radiation in the treatment of advanced carcinoma of cervix. Indian Journal of Cancer, 43 (2): 54-59.

13. Mookerjee A, Mookerjee Basu J, Dutta P , Majumder S, Bhattacharyya S, Biswas J, Pal S, Mukherjee P, Raha S, Baral RN, Das T, Efferth T, Sa G, Roy S, Choudhuri SK (2006) Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis. Clin Cancer Res. 15;12 (14):4339-4349.

14. Bose A, Ghosh D, Pal S, Mukherjee KK, Biswas J, Baral R (2006) Interferon Alpha2B augments suppressed immune functions in tobacco-related head and neck squamous cell carcinoma patients by modulating cytokine signaling. Oral Oncol, 42 (2):161-171.

15. Basu P. Biswas J, Mandal R, Choudhury P (2006) Is interferon-a and retinoic acid combination along with radiation superior to chemo-radiation in the treatment of advanced carcinoma of cervix? Indian J Cancer, 43: 54-59.

16. Choudhuri SK, Mookerjee A, Chatterjee S, Biswas J (2007) A novel approach of overcoming multidrug resistance in cancer through immunomodulation. International Journal of Molecular Medicine, 20(1): S5.

17. Choudhuri SK, Chatterjee S, Ganguli A, Biswas J (2008) Overcoming Multidrug Resistance (MDR) in cancer through immune modulation by. Proceedings for International Symposium on Novel Strategies for Targeted Prevention and Treatment of Cancer, 19-20.

18. S. Majumder , S. Chatterjee, Smarajit Pal, Biswas Jaydip, T. Efferth, Soumitra Kumar Choudhuri (2009) The role of copper in drug-resistant murine and human tumors BY. Biometals, 22 (2): 377

19. Chatterjee S, Mookerjee A, Mookerjee Basu J, Chakraborty P, Ganguly A, Adhikary A, Mukhopadhyay D, Ganguli S, Banerjee R, Ashraf M, Biswas J, Das PK, Sa G, Chatterjee M, Das T, Choudhuri SK (2009) A novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cells. PLOS ONE, 4 (9): E7048.

20. Choudhuri SK, Chatterjee S, Ganguly A, Biswas J (2009)The role of a novel copper chelate in overcoming multidrug resistance in cancer. Proceedings of diabetes mellitus and cancer, Annamalai University, Tamilnadu, 65-70.

21. Ashraf M, Biswas J, Gupta S (2009) Determinants of wound infections for breast procedures: assessment of the risk of wound infection posed by an invasive procedure for subsequent operation. International Journal of Surgery, 7: 543-546.

22. Ashraf M, Biswas J, Majumdar S, Nayak S, Alam N, Mukherjee KK, Gupta S. (2009) Tamoxifen use in Indian women-adverse effects revisited. Asian Pacific J Cancer Prev., 10: 609-612.

23. Basu P, De P, Mandal S, Ray K, Biswas J (2009) Study of 'patterns of care' of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern India. Indian J Cancer. 46(1): 28-33.

24. Dutta K, Biswas J (2009) Influence of dietary habits, physical activity and affluence factors on breast cancer in east India - a case control study. Asian Pacific Journal of Cancer Prevention. 10: 217.

25. Basu P, De P, Mandal S, Ray K, Biswas J (2009) Study of 'patterns of care' of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern India. Indian Journal of Cancer, 46: 28-33.

26. Mita A C, Heist R S, Aren O, Mainwaring P N, Bazhenova L, Gadgeel S M, Blum R H, Polikoff J, Biswas J (2010) Phase II study of Docetaxel with or without plinabulin (NPI-2358) in patients with non small cell lung cancer (NSCLC). J Clin Oncol, 28:15 s.

27. Biswas J, Sinha D, Mukherjee S, Roy S, Siddiqi M, Roy M (2010) Curcumin protects DNA damage in a chronically arsenic-exposed population of West Bengal. Human and Experimental Toxicology, 29(6): 513–524.

28. Biswas J, Roy S, Mukherjee S, Sinha D, Roy M (2010) Indian Spice curcumin may be an effective strategy to combat the genotoxicity of arsenic in Swiss albino mice. Asian Pacific J Cancer Prevention. 11: 239-247.

29. Ashraf M, Jha JK, Mukherjee N, Panda CK, Nayak S, Jadhav TS, Dikshit N, Nath NC, Chakraborty J, Biswas J. (2011) BRCA1 protein expression and its correlation with ER/PR status in sporadic and familial breast cancer in Eastern Indian patients . a hospital based study. J Indian Med Assoc 109: 873-8.

30. Chakraborty K, Bose A, Goswami KK, Mukherjee KK, Ghosh D, Goswami S, Chakraborty T, Sarkar K, Pal S, Bhowmick A, Biswas J, Baral R, (2011) Dysregulated CC receptor-ligand signaling for monocyte chemotaxis in oral squamous cell carcinoma patients is partially rectified by interferon alpha 2b. Human Immunol, 73, 38-47.

31. Roy S, Goswami S, Bose A, Chakraborty T, Chakraborty K, Pal S, Haldar A, Basu PS, Biswas J, Baral R.( 2011) Neem leaf glycoprotein partially rectifies suppressed dendritic cell functions and associated T cell efficacy in stage IIIB cervical cancer patients. Clinical and Vaccine Immunol 18, 571-579.

32. Roy, S., Goswami, S., Bose, A., Goswami, K. K., Sarkar, K., Chakraborty, K., Chakraborty, T., Pal, S., Haldar, A., Basu, P., Biswas, J. and Baral, R. (2011) Defective dendritic cell generation from monocytes is a potential reason for poor therapeutic efficacy of interferon alpha2b (IFNalpha2b) in cervical cancer. Translational Research. 158, 200-213.

33. Roy M, Sinha D, Mukherjee S, Biswas J (2011) Curcumin prevents DNA damage and enhances the repair potential in a chronically arsenic-exposed human population in West Bengal, India. European J Cancer Prevention 20(2):123-131.

34. Roy M, Mukherjee S, Sarkar R , Biswas J (2011) Curcumin sensitizes the effect of chemotherapeutic drugs via modulation of Protein Kinase C, Telomerase, NFkB and Histone Deacetylase in Breast Cancer. Therapeutic Delivery, 2(10): 1275-1293.

35. Roy S, Devleena, Maji T, Choudhuri P, Jaydip Biswas J (2011) Bilateral angiosarcoma of breast in a young lady. Indian J of Medical and Paediatric Oncology, 32(3): 160-161.

36. Roy S, Goswami S, Bose A, Goswami KK, Sarkar K, Chakraborty K, Chakraborty T, Pal S, Haldar A, Basu P, Biswas J, Baral R (2011) Defective dendritic cell generation from monocytes is a potential reason for poor therapeutic efficacy of interferon alpha2b (IFNalpha2b) in cervical cancer. Translational Research. 158: 200-213.

37. Roy S, Goswami S, Bose A, Chakraborty K, Pal S, Haldar A, Basu P, Biswas J, Baral R (2011) Neem leaf glycoprotein partially rectifies suppressed dendritic cell functions and associated T cell efficacy in patients with stage IIIB cervical cancer. Clinical and Vaccine Immunology, 18: 571-579.

38. Dutta S., Begum R, Mazumder (Indra) D., Mandal S. S., Mondal R., Biswas J., Dey B., Panda C. K., Basu P. (2012) Prevalence of Human Papillomavirus in Women Without Cervical Cancer: A Population-based Study in Eastern India. International Journal of Gynecological Pathology 31 (2), 186–191.

39. Mukherjee KK, Bose A, Ghosh D, Sarkar K, Goswami S, Pal S, Biswas J, Baral R. (2012) IFNa2b Augments Immune Responses of Cisplatin+5-Fluorouracil Treated Tongue Squamous Cell Carcinoma Patients. Ind J Med Res, 136, 54-59.

40. Partha Basu, Srabani Mittal, Suchismita Bhaumik, Shyam Sunder Mandal, Anusree Samaddar, Chinmayi Ray, Maqsood Siddiqi, Jaydip Biswas and Rengaswamy Sankaranarayanan. (2012) Prevalence of high risk human papillomavirus and cervical intraepithelial neoplasias in a previously unscreened population – a pooled analysis from three studies. International Journal of Cancer.

41. Mukherjee S, Sarkar R, Biswas J, Roy M (2012) Curcumin inhibits histone deacetylase leading to cell cycle arrest and apoptosis via upregulation of p21 in breast cancer cell lines. Int J Green nanotech, 4: 183-197.

42. Ghosh I, Ghosh P, Bharti AC, Mandal R, Biswas J, Basu P (2012) Prevalence of Human Papillomavirus and Co-Existent Sexually Transmitted Infections among Female Sex Workers, Men having Sex with Men and Injectible Drug abusers from Eastern India. Asian Pacific J Cancer Prevention, 13(3).

43. Dutta S, Begum R, Mazumder D, Mandal SS, Mondal , Biswas J, Dey B Panda CK, Basu P (2012). Prevalence of Human Papillomavirus in Women without Ceraical Cancer: A Population-based Study in Eastern India. Int J Gynecol Pathol, 31(2):178-183.

44. Roy M, Mukherjee S, Biswas J (2012). Inhibition of an epigenetic modulator, histone deacetylase by PEITC in breast cancer - a detailed mechanistic approach. International Journal of Therapeutic Applications, 5:1 – 13.

45. Sarkar R, Mukherjee S, Biswas J, Roy M (2012) Sulphoraphane, a naturally occurring isothiocyanate induces apoptosis in breast cancer cells by targeting heat shock proteins. Biochem and Biophys Res Comm, 427: 80–85.

46. Sinha D, Biswas J, Sung B, Aggarwal B B, Bishayee A. (2012) Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr Drug Targets. Dec;13(14):1799-819.

47. Basu P, Kamal M, Ray C, Biswas J et al. (2013). Inter-observer agreement in the reporting of cervical biopsy specimens obtained from women screened by Visual Inspection with Acetic Acid and Hybrid Capture 2. International Journal of Gynecological Pathology. 32(5):509-515

48. Basu P, Mittal S, Bhaumik S, Mandal S, Samaddar A, Ray C, Siddiqi M, Biswas J, Sankaranarayanan R. (2013). Prevalence of high-risk human papillomavirus and cervical intraepithelial neoplasias in a previously unscreened population—A pooled analysis from three studies. International J. Cancer 132(7):1693-1699.

49. Dutta K, Nanda DP, Hajra S, Biswas J, Sinha D. (2013). Association of matrix metalloproteinase -9 with tumor progression of oral cancer. Indian Journal of Cancer. 50 (1); pp:S271.

50. Basu P, Banerjee D, Singh P, Bhattacharya C, Biswas J (2013) Efficacy and safety of human papilloma virus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and National programmes. South Asian J Cancer, 2:187-192.

51. Goswami KK, Barik S, Banerjee S, Bhowmick AK, Biswas J, Bose A, Baral R. (2013). Supraglottic laryngeal tumor microenvironmental factors facilitate STAT3 dependent pro-tumorigenic switch in tumor associated macrophages to render utmost immune evasion. Immunol Lett 156: 7-17.

52. Basu P., Dutta S., Begum R., Mittal S., Das Dutta P., Bharti A.C., Panda C. K., Biswas J., Dey B., Talwar G. P., Das B. C. (2013). Clearance of Cervical Human Papillomavirus Infection by Topical Application of Curcumin and Curcumin Containing Polyherbal Cream: A Phase II Randomized Controlled Study. Asian Pac J Cancer Prev, 14 (10), 5753-5759.

53. Nanda DP, Sil H, Moulik S, Biswas J, Mandal S, Chatterjee A. (2013). Matrix metalloproteinase-9 as a potential tumor in breast cancer. J Environ Pathol Toxicol Oncol. 32(2):115-29.

54. Roy S, Devleena, Maji T, Chaudhuri P, Lahiri D, Biswas J (2013) Tumor bed boost in breast cancer: Brachytherapy versus electron beam. Indian journal of medical and paediatric oncology. 34(4): 257-263.

55. Basu P, Kamat M, Roy C, Bhat D, Ghosh I, Mitra S, Chatterjee S, Samaddar A, Biswas J. (2013) Inter-observer agreement in the reporting of cervical biopsy specimens obtained from women screened by visual inspection with acetic acid and hybrid capture 2. Int J Gyn Pathol. 32(5):509-15.

56. Roy S, Barik S, Banerjee S, Pal S, Basu PS, Biswas J, Goswami S, Chakraborty T, Bose A, Baral R. (2013). Neem leaf glycoprotein overcomes indoleamine 2, 3 dioxygenase mediated tolerance in dendritic cells by attenuating hyperactive regulatory T cells in cervical cancer stage IIIB patients. Human Immunol, 74, 1015-23.

57. Sarkar S., Maiti G. P., Jha J., Biswas J., Roy A., Roychoudhury S., Sharp T., Panda C.K. (2013). Reduction of proliferation and induction of apoptosis are associated with shrinkage of head and neck squamous cell carcinoma due to neoadjuvant chemotherapy. Asian Pac J Cancer Prev, 14 (11), 6419-6425.

58. Biswas J, Mandal G K, Mukhopadhyay A K, Diwan K, Chakraborty (Chanda) S, Dash S (2014) A very rare association of hereditary breast cancer – pregnancy associated, with familial conjoint twin of rarest variety, Nepal J Med Sciences, 3(1), 68-71.

59. Nanda D P, Datta K, Ganguly K K, Hajra S, Mandal S S, Biswas J, Sinha D (2014) MMP-9 as a potential biomarker for carcinoma of oral cavity: a study in Eastern India, Neoplasma, 61(6), 747-757.

60. Roy M, Mukherjee A, Sarkar R, Mukherjee S, Biswas J (2014) In search of natural remediation for cervical cancer. Anti-Cancer Agents in Medicinal Chemistry, 14(10) (Epub ahead of print).

61. Sarkar R, Mukherjee A, Mukherjee S, Biswas R, Biswas J, Roy M (2014) Curcumin augments the efficacy of antitumor drugs used in leukemia by modulation of Heat Shock Proteins via HDAC6. Journal of Environmental Pathology, Toxicology and Oncology 33(3):247–263.

62. Roy M, Mukherjee A, Mukherjee S, Biswas J (2014) Arsenic: an alarming global concern. Int. J Curr Micobl. Ap Sci 3(10): 34-47.

63. Datta K, Roy A, Nanda D, Das I, Guha S, Ghosh D, Sikdar S, Biswas J (2014) Association of breast cancer with sleep pattern – a pilot case control study in a Regional Cancer Centre in South Asia, Asian Pacific J Cancer Prevention, 15.

64. Ghosh I, Mittal S, Banerjee D, Singh P, Dasgupta S, Chatterjee S, Biswas J, Panda C, Basu P (2014) Study of accuracy of colposcopy in VIA and HPV detection-based cervical cancer screening programme, Australian & NZ J Obstetrics & Gynecology, 54: 570-575.

65. Das A, Barik S, Banerjee S, Bose A, Sarkar K, Biswas J, Baral R, Pal S, (2014) A monoclonal antibody against neem leaf glycoprotein recognizes carcinoembryonic antigen (CEA) and restricts CEA expressing tumor growth. J Immunother, 37, 394-406.

66. Das A, Barik S, Bose A, Roy S, Biswas J, Baral R, Pal S. (2014) Murine carcinoma expressing carcinoembryonic antigen-like protein is restricted by antibody against neem leaf glycoprotein. Immunol Lett 162(1 Pt A):132-9.

67. Datta K, Roy A, Nanda DP, Das I, Guha S, Ghosh D, Sikdar S and Biswas J (2014) Association of Breast Cancer with Sleep-Pattern – A Pilot Case Control Study in a Regional Cancer Centre in South Asia. Asian Pacific J Cancer Prev., 15, 1-5.

68. Singha Roy S, Chakraborty P, Biswas J and Bhattacharya S. (2014). 2-[5- selenocyanato-pentyl] -6-amino- benzo [de]isoquinoline-1, 3-dione inhibits angiogenesis, induces p53 dependent mitochondrial apoptosis and enhances therapeutic efficacy of cyclophosphamide. Biochimie, 105: 137-148.

69. Sarkar R, Mukherjee A, Biswas R, Biswas J, Roy M (2014)
Sulphoraphane, by virtue of its antioxidant potential down-regulates HSP90 in leukemia cells. Int. J. Curr. Microbiol. App. Sci, 3(1): 476-486.

70. Roy M, Mukherjee A, Mukherjee S, Biswas J (2014) Phytonutrients from Fruits and Vegetables in Breast Cancer Control. Anticancer properties of fruits and vegetables: A Scientific Review. Publisher: World Scientific Publishing, Singapore, Chapter 3, Page 75-101, edited by Dr Ajaikumar B. Kunnumakkara.

71. Basu P, Samaddar A, Mittal S, Basu U, Chatterjee S, Biswas J (2014) Concordance between Hybrid Capture 2 results performed on cervical samples obtained before and immediately after visual inspection with acetic acid test. Int J Prev Med, 5(2): 52-56.

72. Bhattacharjee A, Basu A, Ghosh P, Biswas J, Bhattacharya S (2014) Protectieve effect of selenium nanoparticle against cyclophosphamide induced hepatotoxicity and genotoxicity in Swiss albino mice. J Biomaterials Applns; 29(2):303-317.

73. Biswas J (2014) Debunk the myths: Oncologic misconceptions. Editorial. Indian J Med Res, 139: 185-187.

74. Goswami KK, Barik S, Sarkar M, Bhowmick A, Biswas J, Bose A, Baral R, (2014) Targeting STAT3 phosphorylation by neem leaf glycoprotein prevents immune evasion exerted by supraglottic laryngeal tumor induced M2 macrophages. Mol Immunol, 59, 119-27.

75. Mittal S, Biswas J, Basu P. (2014). Visual inspection with acetic acid as a screening test for cervical cancer. Biomed Res J 1(1):23-33.

76. Sinha D, Dutta K, Ganguly KK, Biswas J, Bishayee A. (2014) A novel synthetic oleanane triterpenoid suppresses adhesion, migration and invasion of highly metastatic melanoma cells by modulating gelatinase signaling axis. Mol Carcinogenesis, ;54(8):654-67.

77. Arin Bhattacharjee, Abhishek Basu, Prosenjit Ghosh, Biswas J, Sudin Bhattacharya, (2014). Protective effect of Selenium nanoparticle against cyclophosphamide induced hepatotoxicity and genotoxicity in Swiss albino mice. Journal of Biomaterials Applications, Vol. 29(2) 303–317.

78. Basu P, Mittal S, Singh P, Panda C, Dutta S, Mandal R, Das P, Biswas J, Muwonge R, Sankaranarayanan R. (2015). Diagnostic accuracy of VIA and HPV detection as primary and sequential screening tests in a cervical cancer screening demonstration project in India. Int.J.Cancer. 137(4):859-67.

79. Bhagat P, Roy S, Lahiri D, Maji T, Ray D K, Biswas J, Chaudhuri P. (2015). Expedience of conventional radiotherapy in locally advanced cervix cancer: A retrospective analysis. Onc Gas Hep Rep 4:85-90.

80. Chhatui B, Devleena, Roy S, Maji T, Lahiri D, Biswas J. (2015). Immunomodulated anterior chemotherapy followed by concurrent chemoradiotherapy in locally advanced tongue cancer: An Institutional experience. Indian Journal of Medical and Paediatric Oncology: Official Journal of Indian Society of Medical & Paediatric Oncology. 36(1):43-48.

81. Das A, Mondal B, Bose A, Biswas J, Baral R, Pal S. (2015). Therapeutic anti-NLGP monoclonal antibody for carcinoembryonic antigen expressing tumors is nontoxic to Swiss and BALB/c mice, Int Immunopharmacol, 28, 785-793.

82. Dutta S, Chakraborty C, Mandal R, Basu P, Biswas J, Roychoudhury S, Panda C K. (2015). Persistent HPV16/18 infection in Indian women with the A-allele (rs6457617) of HLA-DQB1 and T-allele (rs16944) of IL-1β -511 is associated with development of cervical carcinoma. Cancer Immunology, Immunotherapy Apr 17.(In press).

83. Maiti G. P., Ghosh A., Mondal P., Baral A., Datta S., Samadder S., Nayak S. P., Sikdar N., Chakraborty J., Biswas J., Chowdhury S., Roy B., Roychowdhury S., Panda C. K. (2015). The SNP rs1049430 in the 3'-UTR of SH3GL2 regulates its expression: Clinical and prognostic implications in head and neck squamous cell carcinoma. Biochim Biophys Acta. (Molecular Basis of Disease) 2015 May;1852(5):1059-67.

84. Roy S, Lahiri D, Maji T, Biswas J. Review article on ‘Recurrent Glioblastoma: where we stand’ accepted for publication in South Asian Journal of Cancer.

85. Roy M, Kunnumakkara A B, Mukherjee A, Sarkar R , Mukherjee S and Biswas J (2015) Repair Activity Impaired by Arsenic: Recovery by Phytochemicals, Int. J Curr Micobl. Ap Sci 4(3): 578-587.

86. Mukherjee A, Mukherjee S, Biswas J, Roy M (2015) Phytochemicals in obesity control, Int. J Curr Micobl. Ap Sci 4(4): 558-567.

87. Bhattacharya A, Basu A, Biswas J, Bhattacharya S (2015) Nano-Se attenuates cyclophosphamide-induced pulmonary injury through modulation of oxidative stress and DNA damage in Swiss albino mice. Molecular & Cellular Biochemistry (accepted)

88. Gangopadhyay A, Nath P, Biswas J (2015) Sequential chemoradiation in locally advanced head and neck cancer after induction chemotherapy: an induction chemotherapy schedule more suited to a limited resource setting, ecancer 9: 543

89. Gangopadhyay A, Nath P, Biswas J (2015) Reduced dose intensity of chemotherapy may not lead to inferior palliation in locally advanced carcinoma of the gall bladder: An experience from a regional cancer centre in Eastern India, Journal of Gastrointestinal Cancer, 46 (3): 297-300

90. Biswas J, Roy M and Mukherjee A (2015) Anticancer Drug Development Based on Phytochemicals, J Drug Discovery, Development and Delivery, 2(1): 1012- 1017.

91. Mukherjee A, Biswas J and Roy M (2015) Viral origin of oral cancer: its remediation by phytochemicals, Int J Curr Res Aca Rev, 3(8): 142-150.

92. Basu A, Singha Roy S, Bhattacharjee A, Bhuniya A, Baral R, Biswas J and Bhattacharya S (2015) Vanadium (III)-L-cysteine protects cisplatin-induced nephropathy through activation of Nrf2/HO-I pathway, Free Radical Research, (accepted)

93. Sinha D, Sarkar N, Biswas J and Bishayee A (2016) Resveratrol for breast cancer prevention and therapy: preclinical evidence and molecular mechanisms, Seminars in Cancer Biol (in press)

94. Banerjee K, Das S, Sarkar A, Chatterjee M, Biswas J and Choudhuri S K (2016) A copper chelate induces apoptosis and overcomes multidrug resistance in T-cell acute lymphoblastic leukemia through redox imbalance and inhibition of EGFR/PI3K/Akt expression, Biomedicine & Pharmacotherapy, 84: 71-92.

95. Das S, Biswas J and Choudhuri S K (2016) Potential anticancer drugs targeting immune pathways, (Provisional chapter)

96. Sinha Dona, Sarkar Nivedita, Biswas Jaydip, Bishayee Anupam (2016) Resveratrol for breast cancer prevention and therapy: Preclinical evidence and molecular mechanisms. Seminars in Cancer Biology, 40-41: 209-232.

97. Bhattacharyya Sayantan, Sekar V, Majumder B, Mehrotra D, Banerjee S, Bhowmick A, Alam N, Mandal G, Biswas Jaydip, Majumder P, Murmu N (2016) CDKN2A-p53 mediated antitumor effect of Lupeol in head and neck cancer, Cell Oncol, (Published online: 30 December 2016).

98. Roy M, Mukherjee A, Mukherjee S, Biswas J (2017) Nutraceutials in leukemia, J. Ayu. Herb. Med., 3(1): 41-47.

99. Madhumita Roy, Apurba Mukherjee, Sutapa Mukherjee, Jaydip Biswas (2017) Phytochemicals as an adjuvant in leukemia therapy. eBook on Leukemia: Causes, Symptoms & Treatment

100. Madhumita Roy, Apurba Mukherjee, Sutapa Mukherjee, Jaydip Biswas (2017) Drug Resistance in Leukemia: Remediation by Natural Means. Biomed Res J 2017;4(1) 8-27.



: PARTICIPATION IN CONFERENCES: :

    1. Workshop on Cancer, Chittaranjan National Cancer Hospital, Calcutta, November 1-3, 1986.

    2. Annual Conference, Association of Radiation Oncologists, 1991.

    3. Annual Conference, Association of Radiation Oncologists, 1992.

    4. 3rd European Congress of Surgery, London, UK, September, 14-17, 1993.

    5. Annual Conference, Association of Radiation Oncologists, 1993.

    6. 6th Biennial National Cancer Congress, Indian Society of Oncology, Calcutta, February 4-6, 1994.

    7. First National Conference on Bronchology, Calcutta, March, 11-12, 1995.

    8. Annual Conference, Association of Radiation Oncologists, 1995.

    9. Invited for a Core Group Meeting with the Canadian Medical Team of Professors for assessing CME programme as INDO-CANADIAN Joint Venture in the field of Oncology at Peerless Hospital & B K ROY Research Centre, Calcutta, August 29-31, 1995.

    10. Invited Delegate - Workshop on “TRAINER’S TRAINEE” on Palliative Care including Pain Therapy” sponsored by W. H.O. and Ministry of Health & Family Welfare, Government of India, Calcutta, April, 6-8, 1995.

    11. IASO MID CON ’95 & CME. Indian Association of Surgical Oncology & Association of Surgeons of India, W.B. State Chapter, Calcutta, September 1-3, 1995.

    12. Invited Delegate, Workshop on Thyroid Surgery & Technology Transfer Programme on Head and Neck Cancer, Tata Memorial Hospital, Mumbai, December 22-24, 1996.

    13. Chairperson of a Scientific Session-17TH Annual Conference of the Indian association for Cancer Research & National Symposium on Breast Cancer, Calcutta, January, 21-24, 1998.

    14. Certificate of Achievement in the Training Programme on Patients’ Satisfaction, Quality Assurance and Legal Aspects of Health Care. Organized by Indian Society of Health Administrators, Bangalore, July, 14-18, 1998.

    15. 1ST International Workshop on Palliative Care, Organised by Pain & Palliative Care Society, Kolkata, March, 12-14, 1999.

    16. Chairperson of a Scientific Session - Breast Cancer in the New Millennium, Nagpur, February, 18-20, 2000.

    17. Chairperson of a Scientific Session - 10th Annual Conference of the Association of Gynaecologic Oncologists of India, Kolkata, December, 13-1, 2001.


More

 

 


 

 

Patient Testimonials
Achivements
  • Invited for a Core Group Meeting with the Canadian Medical Team of Professors for assessing CME programme as INDO-CANADIAN Joint Venture in the field of Oncology at Peerless Hospital & B K ROY Research Centre, Calcutta, August 29-31, 1995.
  • Invited Delegate - Workshop on “TRAINER’S TRAINEE” on Palliative Care including Pain Therapy” sponsored by W. H.O. and Ministry of Health & Family Welfare, Government of India, Calcutta, April, 6-8, 1995.
  • IASO MID CON ’95 & CME. Indian Association of Surgical Oncology & Association of Surgeons of India, W.B. State Chapter, Calcutta, September 1-3, 1995.



TRAINING ABROAD:

1) Memorial Sloan Kettering Cancer Centre, New York, USA in Surgical Oncology with special reference to Head and Neck Service (under Prof Jatin P Shah & E W Strong), Breast Service (under Professor D Kinnie & Prof Michael Moore) and Soft Tissue Sarcoma Service and Hepato Billiary Malignancies (under Prof Murray F Brennan)


2) Manchester University Hope Hospital, Salford, UK and Christie Hospital, UK in Surgical Oncology in Relation to Oesophageal and Colorectal Surgery, Gastrointestinal Endoscopy (under Prof Miles Irving & others) and training in Medical Oncology at Christie Hospital, UK.

CLINICAL TRIALS :

(PHASE II TRIALS)

  • A multicenter open-label, phase II study of LEP-ETU for efficacy and safety in patients with metastatic breast cancer.

 

  •  A randomized phase II study comparing erlotinib-pemetrexed, pemetrexed alone, and erlotinib alone, as second-line treatment for non-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer.

 

  • A phase II study of the vascular disrupting agent npi-2358 in combination with docetaxel in patients with advanced non-small-cell-lung-cancer.

 

  • Open label, randomized multicentric clinical trial of mycobacterium w in combination with paclitaxel plus cisplatin versus paclitaxel and cisplatin in advanced non small cell lung cancer.

 

  • A phase 2, randomized, double–masked, placebo-controlled study to evaluate the efficacy of snx-1012 in reducing the duration and severity of ulcerative oral mucositis in patients receiving cytotoxic chemotherapy for breast and lung cancer.

 

  • Phase II study of NRX 195183 therapy for patients with relapsed or refractory acute promyelocytic leukemia.

 

  • Population based evaluation of early detection of cervical cancer precursors by visual inspection with Lugol’s iodine and acetic acid; evaluation of performance of single freeze versus double freeze cryotherapy in treating cervical precancers – a randomized controlled trial.

 

  • Comparative evaluation of early detection of cervical cancer precursors by HPV testing, visual inspection with acetic acid (VIA & VIAM) and with Lugol’s iodine (VILI) in Calcutta, India.

 

  • Evaluation of cervical visual inspection after acetic acid application without (VIA) and with magnification (VIAM) in the early detection of cervix cancer in Calcutta, India.

 

  • A Population Based Cancer Registry based on several epidemiological research studies is under planning.

 

  • Role of curcumin in protecting DNA damage in lymphocytes from human population chronically exposed to arsenic in West Bengal, PI: Dr. Madhumita Roy, co-investigator      Dr. Jaydip Biswas, funding agency: Dept of Biotechnology.

 

  • “Phase II Clinical Trial of Immunotherapy with an Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine in Patients with Stages IIIB/IV Non-Small Cell Lung Cancer That Have Completed First Line Chemotherapy.”

 

(PHASE III TRIALS)

  • A phase III study of ERBB2 positive advanced or metastatic gastric or esophageal or gastroesophageal junction adenocarcinoma treated with capecitabine plus oxaliplatin with or without lapatinib.

 

  • Randomized phase III study of larotaxel + cisplatin (lc) vs. gemcitabine + cisplatin (gc) in the first line treatment of locally advanced/ metastatic urothelial tract or bladder cancer.

 

  • A phase III study of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant.

 

  • A randomized, double-blind, placebo-controlled, phase 3 study to assess the efficacy and safety of weekly farletuzumab  (MORAB-003) in combination with carboplatin and taxane in subjects with platinum-sensitive ovarian cancer in first relapse.

 

  • Investigations on the clearance of human papillomavirus infection in uterine cervix by basant, polyherbal vaginal cream and curcumin.

 

  • A two-arm, randomized clinical trial to evaluate concomitant immunotherapy (with interferon-Alpha and retinoic acid) and radiation therapy for the treatment of advanced cervical cancer in India.

 

  • A phase IIIB, double blind, randomized, controlled study to evaluate the immunogenicity & safety of Glaxo-Smithkline biological’s HPV-16/18 VLP/AS04 vaccine administered intramuscularly according to a 0,1,6 month schedule in healthy Indian female subjects aged 18-35 years.

 

  • A multinational, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ave5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy.

 

  • A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy.

 

 

(Phase IV Trials)

  • A multi-centre, open label, Phase IV, Interventional study to evaluate the efficacy of  Erlotinib (Tarceva®) following 4 cycles of platinum based chemotherapy in patients with locally advanced or metastatic non small cell lung cancer (NSCLC) who have not experienced disease progression or unacceptable toxicity during chemotherapy.

 

Active Implementation of Quality of Life(QOL) Assessment in Clinical Practice for Patients with Advanced NSCLC and Comparison of QOL and Response Endpoints.

 

 

 


 

 

 

 

 

 

 

 

"CANCER DOES NOT KILL BUT DELAY DOES !" "EARLY DETECTION CAN CURE CANCER" "THE MIRROR CAN SAVE YOUR LIFE; CHECK YOURSELF MONTHLY, DETECT CANCER EARLY" "TREAT THE TREATABLE, PREVENT THE PREVENTABLE" "LEAD A HEALTHY LIFE, BEAT CANCER"

 

Copyright@Dr.jaydip Biswas 2011 all right reserved